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Single‑cell profiling of human dura
and meningioma reveals cellular meningeal
landscape and insights into meningioma
immune response
Anthony Z. Wang1,2,3,4,5†, Jay A. Bowman‑Kirigin1,2,3,4†, Rupen Desai1,4, Liang‑I Kang6, Pujan R. Patel7,
Bhuvic Patel1,4, Saad M. Khan1,4, Diane Bender3, M. Caleb Marlin8, Jingxian Liu9,10, Joshua W. Osbun1,4,
Eric C. Leuthardt1,4, Michael R. Chicoine1,4, Ralph G. Dacey Jr1,4, Gregory J. Zipfel1,4, Albert H. Kim1,4,
David G. DeNardo11, Allegra A. Petti1,4,9,12*† and Gavin P. Dunn5*†

Abstract
Background: Recent investigations of the meninges have highlighted the importance of the dura layer in central
nervous system immune surveillance beyond a purely structural role. However, our understanding of the meninges
largely stems from the use of pre-clinical models rather than human samples.
Methods: Single-cell RNA sequencing of seven non-tumor-associated human dura samples and six primary menin‑
gioma tumor samples (4 matched and 2 non-matched) was performed. Cell type identities, gene expression profiles,
and T cell receptor expression were analyzed. Copy number variant (CNV) analysis was performed to identify putative
tumor cells and analyze intratumoral CNV heterogeneity. Immunohistochemistry and imaging mass cytometry was
performed on selected samples to validate protein expression and reveal spatial localization of select protein markers.
Results: In this study, we use single-cell RNA sequencing to perform the first characterization of both non-tumorassociated human dura and primary meningioma samples. First, we reveal a complex immune microenvironment
in human dura that is transcriptionally distinct from that of meningioma. In addition, we characterize a functionally
diverse and heterogenous landscape of non-immune cells including endothelial cells and fibroblasts. Through imag‑
ing mass cytometry, we highlight the spatial relationship among immune cell types and vasculature in non-tumorassociated dura. Utilizing T cell receptor sequencing, we show significant TCR overlap between matched dura and
meningioma samples. Finally, we report copy number variant heterogeneity within our meningioma samples.
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Conclusions: Our comprehensive investigation of both the immune and non-immune cellular landscapes of human
dura and meningioma at single-cell resolution builds upon previously published data in murine models and provides
new insight into previously uncharacterized roles of human dura.
Keywords: Single-cell RNA sequencing, Dura, Meninges, Imaging mass cytometry

Background
The central nervous system (CNS) in vertebrates is
encased by three layers of tissue that together comprise the meninges [1]. The outermost layer of tissue is
the dura mater, the middle layer is the arachnoid mater,
and the innermost layer is the pia mater, which adheres
to the brain surface. The dura layer performs important
structural roles in the CN S[2]. Specifically, this layer
protects the underlying brain and spinal cord, harbors
the large vascular sinus and lymphatic vessels through
which venous and lymphatic drainage of the brain traverses, and creates intracranial compartments that divide
the cerebral hemispheres and separate them from the
cerebellum of the posterior fossa [2–4]. Combined, the
dura and arachnoid mater form a water-tight seal to contain cerebrospinal fluid which originates from the choroid plexus and bathes the brain before exiting through
arachnoid granulations, in addition to other routes such
as the cribriform plate [5, 6]. Thus, the dura is critical in
establishing the anatomic compartments of the brain and
in performing other protective roles.
Beyond its structural roles, the meninges consist of
cells which also perform critical functional roles in the
CNS. The embryonic meninges influence the development of the skull, neuronal migration and anatomic positioning, neurogenesis and blood vessel development, and
the establishment of basement membranes of the pia
and the glia limitans [reviewed in [1, 7]]. Recently, there
has been a growing appreciation that the dura also harbors vital immunologic functions, in addition to its role
as a physical barrier in the innate immune response of
the brain, thereby supporting the view that the meninges represent a dynamic immune microenvironment
involved in organizing CNS immune responses. First,
several studies in mice have shown that the dura harbors
a range of immune cell types including macrophages,
monocytes, dendritic cells (DCs), and T and B cells [8–
10]. Second, meningeal immunity is critical to immune
responses against stroke, traumatic brain injury, infection, and cancer [11–14]. Finally, recent identification
of lymphatic channels in the dura has illuminated new
mechanisms by which the CNS interacts with systemic
immunity [15, 16]. Several examples have demonstrated
that modulating various functions of the dura can alter
the immune response. For example, investigators showed
that the CNS anti-tumor immune response can be

attenuated by ligation of cervical lymphatics originating
from the dura [7] and, conversely, that CNS anti-tumor
immune responses can be enhanced by the induction of
dural lymphangiogenesis [17]. Furthermore, clinicians
have explored endovascular embolization of the middle meningeal artery—which perfuses the dura—for the
treatment of chronic subdural hematomas [18]. Thus,
clarifying the cellular composition of dura may enable a
better understanding of this tissue site, with important
translational implications.
Because much of our understanding of meningeal biology stems almost entirely from pre-clinical models, we
focused our work on characterizing meningeal composition in patients undergoing surgery for the resection of
intracranial meningiomas as this is one of the few scenarios in which dura resection is clinically indicated. Meningiomas are common, typically benign, tumors originating
from within the meninges and treated by surgical resection of the meningioma and nearby surrounding margin
of dura, some of which is not grossly associated with the
tumor as determined by the surgeon [19, 20]. Herein,
we report the first characterization of human dura using
single-cell RNA sequencing (scRNA-seq) by profiling
the surrounding non-tumor-associated dura and a subset of matched meningiomas from patients undergoing
surgical resection. In total, seven non-tumor-associated
human dura samples, four matched primary meningioma
tumor samples, and two non-matched primary meningioma tumor samples were analyzed. We show using
scRNA-seq that human dura consists of diverse immune,
endothelial, and mesenchymal cell types. We supplemented these observations with imaging mass cytometry (IMC), which allowed us to investigate the spatial
relationships among these cell types, and immunohistochemistry (IHC), which allowed us to compare the
expression of several markers between matched dura and
tumor samples. Moreover, from the scRNA-seq data, we
observed cellular heterogeneity and functional diversity
within each cell population characterized. In patientmatched dura and meningioma tumors, we observed
that immune cell states were distinct within each tissue.
Additionally, using single-cell TCR sequencing, we show
that dura that is tumor-adjacent, but not tumor-attached;
harbors clonotypic T cell diversity; and shares T cell clonotypes with adjacent meningioma tumor tissue. Finally,
we provide evidence of copy number heterogeneity in
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primary meningioma tumor samples at the single-cell
level. Together, these findings provide further support
that the dura is a dynamic anatomic tissue site and suggest cellular pathways by which the immune response to
meningiomas evolve.

Methods
Experimental design

The objective of this study was to characterize the cellular composition of human dura and meningioma at a single-cell resolution. The study design involved performing
3′ and 5′ single-cell RNA sequencing, with V(D) J enrichment for select samples, in addition to imaging mass
cytometry and immunohistochemistry.
Patient recruitment and sample collection

Adult patients undergoing neurosurgical intervention at
Barnes-Jewish Hospital were screened. Selection criteria
included (1) age > 18 years and (2) presence of intracranial meningioma with clinical indications for surgical resection. All samples were collected from patients
undergoing surgical resection for a primary meningioma tumor, except for SAMPLE06 (DURA06) which
was collected from a patient undergoing surgical resection for a recurrent meningioma tumor. Prior to surgery,
informed consent was obtained from patients meeting
selection criteria following the Washington University
School of Medicine Institutional Review Board Protocol
#202107071. During surgical resection, specimens were
placed in normal saline and immediately maintained on
ice pending further processing. Clinical characteristics
are summarized in Additional file 1: Table S1.
Sample extraction and preparation

Dura and matched tumor samples (SAMPLE02, 05, 06,
08, 09, 10, 11, and 13) were collected from the operating
room on ice. Excess sample was blotted dry and frozen in
Fisher Healthcare Tissue-Plus Optimal Cutting Temperature (O.C.T.) Compound (Fisher Scientific) on dry ice and
stored at –80°C. To disaggregate the remaining samples,
samples were placed in a sterile-filtered medium containing 10%FBS (Lonza), IMDM (Lonza), 2 mg/mL collagenase A (Roche), and 2 mg/mL collagenase D (Roche)
and macerated into small pieces with a scalpel. Samples
were incubated overnight at 37°C with 5% CO2, with gentle pipetting intermittently to encourage further disaggregation. The following morning, after the collagen matrix
had completely dissolved and the cells had dissociated
into a single-cell suspension, the cell suspension was
passed through a 100-μm strainer, followed by RBC lysis
with ACK buffer (Lonza), followed by passing through a
70-μm strainer and then a 40-μm strainer. If a significant
portion of the cells were dead, samples were subjected to
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 asySepTM dead cell removal per manufacturer’s protocol
E
(Stemcell Technologies). If the suspension had considerable debris, samples were subjected to debris removal
solution according to manufacturer’s instructions (Miltenyi Biotec). Cells were resuspended in 10% FBS/IMDM in
preparation for construction of single-cell libraries.
Meningioma samples (MEN104 and MEN108) were
collected from the operating room on ice and the majority of the sample was macerated with a scalpel. Samples
were processed following the human tumor dissociation
kit (Miltenyi Biotec) using the tough gentleMACS program on the gentleMACs Octo Dissociator with Heaters (Miltenyi Biotec). Samples were then passed through
a 70-μm filter, subjected to RBC lysis with ACK buffer
(Lonza), and then sorted with CD45 MicroBeads (Miltenyi Biotec). Both CD45-positive and CD45-negative fractions were then submitted for sequencing. Excess sample
was washed in PBS and fixed in 10% formalin for 24 h.
Afterwards, excess samples were transferred to 70% ethanol and embedded in paraffin.
Single‑cell RNA sequencing

Cell suspensions were prepared according to the manufacturer’s protocol (10x genomics) for 3′ v3 single-cell
sequencing or 5′ single-cell sequencing with TCR enrichment (Additional file 1: Table S1). For both methods, gel
beads in emulsion (GEMs) were generated from a mixture of cell suspension combined with the GEM beads
subjected to emulsion production by the Chromium
Controller. cDNA was prepared after the GEM generation and barcoding, followed by the GEM-RT reaction
and bead cleanup steps. Purified cDNA was amplified
for 10–14 cycles before being cleaned up using SPRIselect beads. Samples were then run on a tape station or
Bioanalyzer to determine the cDNA concentration. TCR
enrichments were done on the full-length cDNA 5′ gene
expression libraries (GEX). Both GEX and Enriched TCR
libraries were prepared as recommended by the 10x
Genomics Chromium Single Cell V(D) J Reagent Kits (v1
Chemistry) user guide with appropriate modifications to
the PCR cycles based on the calculated cDNA concentration. For sample preparation on the 10x Genomics
platform for 3′v3 libraries, the Chromium Single Cell 3′
GEM, Library & Gel Bead Kit v3 (PN-1000075) with the
Chromium Single Cell Chip B Kit (PN-1000154) were
used. For 5′ libraries the Chromium Single Cell 5′ Library
and Gel Bead Kit (PN-1000006), Chromium Single Cell
A Chip Kit (PN-1000152), Chromium Single Cell V(D) J
Enrichment Kit, Human, T cell (96 rxns) (PN-1000005),
and Chromium Single Index Kit T (PN-1000213) were
used. The concentration of each library was accurately
determined through qPCR utilizing the KAPA library
Quantification Kit according to the manufacturer’s
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protocol (KAPA Biosystems/Roche) to produce cluster counts appropriate for the Illumina NovaSeq6000
instrument. Normalized libraries were sequenced on a
NovaSeq6000 S4 Flow Cell using the XP workflow and a
151×10×10×151 sequencing recipe according to manufacturer protocol for 5′ sequencing and a 28×8×98
sequencing recipe according to manufacturer protocol
for 3′v3 sequencing. For both sequencing approaches, a
median sequencing depth of 50,000 reads/cell was targeted for each Gene Expression Library and 5000 reads/
cell for each V(D) J (T cell) library generated from the 5′
sequencing library.
Single‑cell RNA‑seq data processing of dura
and meningioma samples

Raw sequencing data was processed with the CellRanger pipeline (10x Genomics, default settings, version
3.0.1) mapped onto a human genome GRCh38-3.0.0. All
seven dura samples were then processed using the Seurat R package [21] and cells that contained fewer than
500 features, more than 10% mitochondrial transcripts,
and a nCount value greater than the 93rd percentile of
each individual sample were removed. Cells containing greater than 6000 nFeatures were removed from the
DURA08 sample. Samples were then batched according to sequencing technology (3′ or 5′ sequencing) and
each batch was individually log normalized after which
variable features were selected according to default settings. Both batches were then integrated using FindIntegrationAnchors and IntegrateData. Principal component
analysis was then performed and the optimal number of
principal components (PCs) was determined based upon
results from the elbow plots, jackstraw resampling, and
PC expression heatmaps (n=50). Dimensionality reduction and visualization were performed with the uniform
manifold approximation and projection (UMAP) algorithm [22] (Seurat implementation) and unsupervised
graph-based clustering was performed at a resolution of
0.7. Cell cycle phase was assessed based on expression of
phase-specific genes following methodology provided by
Seurat [23].
Similarly, four paired dura and meningioma samples
were processed together using the Seurat R package.
Similar filtering criteria were applied, but samples were
merged, rather than batched and integrated (because the
same sequencing technology was used), then normalized.
Variable features were selected according to default settings and principal component analysis was performed.
The optimal number of principal components was determined (n=50) and dimensionality reduction and visualization were performed with the UMAP algorithm.
Unsupervised graph-based clustering was performed
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at a resolution of 0.7 and cell cycle phase was similarly
assessed.
Finally, DURA09, MEN09, MEN104.1 (CD45+ fraction), MEN104.2 (CD45− fraction), MEN108.1 (CD45+
fraction), and MEN108.2 (CD45− fraction) samples were
processed together using the Seurat R package. Similar
filtering criteria were applied, and samples were merged
and normalized. Variable features were selected according to default settings and principal component analysis
was performed. The optimal number of principal components was determined (n=40) and dimensionality reduction and visualization were performed with the UMAP
algorithm. Unsupervised graph-based clustering was
performed at a resolution of 0.7 and cell cycle phase was
similarly assessed.
Differentially expressed genes of each cluster resolved
by unsupervised graph-based clustering were determined
using a Wilcoxon rank-sum test-based function. These
genes, along with commonly defined markers (Additional
file 1: Table S2), were used to identify cell identity.
Subpopulations of cells were isolated based on cell
type classification (i.e., immune, non-immune, monocyte/macrophage, etc.), after which each subpopulation
was rescaled. Variable genes were not recalculated for
integrated data sets and recalculated for non-integrated
data sets. Principal component analysis was performed
and an appropriate number of principal components
selected (dura immune cells: n=30, dura myeloid cells:
n=20, dura DCs: n=15, dura non-immune cells: n=30,
dura endothelial cells: n=20, dura fibroblasts: n=20, dura
and tumor immune cells: n=30, dura and tumor myeloid
cells: n=15, dura and tumor DCs: n=15, dura and tumor
macrophages: n=15, dura and tumor non-immune cells:
n=30, aggregated tumor cells: n=30, MEN09 tumor cells:
n=20, MEN104 tumor cells: n=15, and MEN108 tumor
cells: n=14). Dimensionality reduction and visualization
were performed with the UMAP algorithm and unsupervised graph-based clustering was performed at the following resolutions (dura immune cells: 1.0, dura myeloid
cells: 0.6, dura DCs: 0.9, dura non-immune cells: 0.9,
dura endothelial cells: 0.7, dura fibroblasts: 0.8, dura and
tumor immune cells: 0.7, dura and tumor myeloid cells:
0.8, dura and tumor DCs: 0.7, dura and tumor monocyte/
macrophages: 0.9, dura and tumor non-immune cells:
0.8, aggregated tumor cells: 0.7, MEN09 tumor cells: 0.8,
MEN104 tumor cells: 0.8, and MEN108 tumor cells: 0.7).
Immunohistochemistry validation of antibodies
and antibody conjugation for imaging mass cytometry

Purchased antibodies (Additional file 1: Table S3) were
initially tested via immunohistochemistry. Respective
positive control tissues for each antibody were tested
(Novus Biologicals). Slides were first baked in an oven
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at 56 °C overnight to melt the paraffin wax, then placed
in xylene for 20 min, and rehydrated in the following
metal-free solutions of ethanol for 5 min each: 100%,
100%, 95%, 95%, 80%, 80%, 70%, and 70%. After rehydration, slides were placed in metal-free water for 5 min on
an orbital shaker after which they were incubated in pH
9 IHC Antigen Retrieval Solution (Invitrogen) at 96°C
for 30 min. Slides were cooled in the antigen retrieval
solution for 10 min at room temperature, followed by a
10-min wash in metal-free water and a 10-min wash in
metal-free PBS. The tissues on the slides were outlined
with a hydrophobic barrier pen (Liquid Blocker) and a
solution of 3% bovine serum albumin (BSA) in PBS was
placed on the tissues within the hydrophobic barriers
for 45 min at room temperature. The primary antibody
solution was prepared at manufacturer-recommended
dilutions in PBS with a final concentration of 0.5% BSA
and subsequently added following removal of the 3%
BSA solution. The primary antibody solution was incubated on the tissues overnight at 4°C. Slides were placed
within a hydration chamber during this time. Following
overnight incubation, the slides were then washed in
0.2% Triton-X 100 in PBS for 10 min twice and washed in
PBS for 10 min twice. Secondary antibody solution was
prepared similar to the primary antibody solution with
secondary antibody diluted following manufacturer recommendations in PBS with a final concentration of 0.5%
BSA. Slides were incubated with secondary antibody
solution away from light for 45 min at room temperature
and then washed in 0.2% Triton-X 100 in metal-free PBS
for 10 min, twice, and then in metal-free PBS for 10 min,
twice. Slides were then treated with 3-uM DAPI solution
for 2 min away from light and subsequently washed in
metal-free PBS for 10 min. Tissues were then mounted
with coverslips using Vectashield Plus Antifade Mounting Medium (Vector Laboratories) and sealed with clear
nail polish (Revlon 771). Tissues were imaged on Zeiss
LSM 880 with oil immersion.
Antibodies with successful positive staining were subsequently conjugated to lanthanide metals (Additional
file 1: Table S3) following the protocol associated with the
Maxpar X8 Antibody Labeling Kit (Fluidigm).
Imaging mass cytometry

Dura and tumor samples frozen in O.C.T. at −80°C were
thawed, removed from O.C.T., and immediately fixed in
10% neutral buffered formalin for 22 h. Samples were
then transferred to 70% metal-free ethanol, embedded
in paraffin wax, and sectioned at a thickness of 5 um
onto standard slides. Slides were baked in an oven at
56°C overnight to melt the paraffin wax and then placed
in xylene for 20 min and then rehydrated in the following metal-free solutions of ethanol for 5 min each: 100%,
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100%, 95%, 95%, 80%, 80%, 70%, and 70%. After rehydration, slides were placed in metal-free water for 5 min on
an orbital shaker and then incubated in pH 9 IHC Antigen Retrieval Solution (Invitrogen) at 96°C for 30 min.
Slides were cooled in the antigen retrieval solution for
10 min at room temperature and washed in metal-free
water for 10 min and metal-free PBS for 10 min. The tissues on the slides were outlined with a hydrophobic barrier pen (Liquid Blocker), and a solution of 3% bovine
serum albumin (BSA) in PBS was placed on the tissues
within the hydrophobic barriers for 45 min at room
temperature. The lanthanide-conjugated antibody solution, with respective dilutions as outlined in Additional
file 1: Table S3, was prepared in PBS with a final concentration of 0.5% BSA. This antibody solution was placed
on the tissues within the hydrophobic barrier following
removal of the 3% BSA solution. Slides were incubated
with this antibody solution overnight at 4°C in a hydration chamber. Following overnight incubation, the slides
were then washed in 0.2% Triton-X 100 in PBS for 8 min,
twice. They were then washed in PBS for 8 min, twice.
DNA-Intercalator (Fluidigm) solution was prepared in
PBS at a dilution of 1:400 and incubated on the tissues
within the hydrophobic barrier for 30 min at room temperature. Slides were washed in metal-free water for 5
min and then air-dried for 20 min. The prepared slides
were imaged on the Hyperion System (Fluidigm). Imaging results were visualized through MCD Viewer (Fluidigm) and saved as 16-bit TIFF images. Individual channel
intensities were manually selected and standardized
throughout all images.
Expression heatmaps and gene functional enrichment
analysis

Expression heatmaps were generated by selecting the
n most highly weighted genes in each of the top m PCs
(n and m are indicated in the text corresponding to each
heatmap). The expression of each gene was averaged
within each cluster and scaled and the results were hierarchically clustered using heatmap2. Gene functional
enrichment analysis was performed using ToppGene
(https://toppgene.cchmc.org/enrichment.jsp) [24]. Hierarchically clustered gene groups were selected and the
top one or two gene ontology biological pathways were
displayed. All gene groups are listed in Additional file 2.
Macrophage polarization, meningeal macrophage,
and microglial scores

Macrophage polarization, meningeal macrophage, and
microglial scores were generated using AddModuleScore
(Seurat implementation) and previously published gene
lists [10, 25, 26].
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Immunohistochemical staining of somatostatin receptor 2
and macrophage markers

Formalin-fixed, paraffin-embedded (FFPE) tissues were
sectioned into 5-μm sections using a microtome and
baked at 55-60°C for 2 h. FFPE sections were stained
with hematoxylin and eosin (Thermo Fisher). Automated
immunohistochemical staining was performed on the
BOND Rxm (Leica Biosystems) on FFPE sections, using
the Bond Polymer Refine Detection kit (DAB-based) for
both mouse and rabbit primary antibodies (Leica Biosystems). Following baking and dewaxing, appropriate antigen retrieval was performed with citrate-based
(ER1) or high-PH (ER2) buffers for 20 min. After endogenous peroxidase block and non-specific protein blocking (2.5% BSA with 5% goat serum in PBS), tissues were
incubated in primary antibody for 60 min. Primary
antibodies (diluted in blocking buffer) and dilutions
used were as follows: rabbit Anti-Iba1 antibody [clone
EPR16588] 1:200 (ab178846; Abcam), rabbit Anti-Mannose Receptor antibody 1:2000 (ab64693; Abcam), rabbit
Anti-TMEM119 antibody-C-terminal 1:250 (ab185333;
Abcam), rabbit Anti-Somatostatin Receptor 2 antibody
[UMB1]-C-terminal 1:1000 (ab134152; Abcam), and
mouse Anti-CD163 1:200 (NCL-L-CD163; Leica) (Additional file 1: Table S2). After polymer-based anti-rabbit or
anti-mouse labeling with HRP, tissues were chromogenically developed with DAB for 10 min and counterstained
with hematoxylin. Slides were dehydrated and mounted
using xylene-based Cytoseal (Thermo Fisher).
Image analysis of IHC of somatostatin receptor 2
and macrophage markers

Whole-slide scans were obtained on a Zeiss Axioscan
Z1 brightfield slide scanner using a 20× objective lens.
Whole-slide scans were analyzed using HALO software
(Indica Labs) using the algorithm Area Quantification
v2.1.11, quantifying the percent area positive for the indicated marker in the total analyzed area. Representative
areas were also captured and assembled into panels using
HALO software (Indica labs).
TCR analysis

Raw TCR sequencing data was processed with the Cellranger V(D) J pipeline (10x genomics, default settings,
version 2.0.0) mapped onto a human VDJ reference
GRCh38-2.0.0. Clonotype analysis was performed using
the scRepertoire R package [27]. All data processing was
performed as outlined at https://github.com/ncborcherd
ing/scRepertoire. The following clonotype states were as
defined: hyperexpanded (50 < X ≤ 150), large (20 < X ≤
50), medium (5 < X ≤ 20), small (1 < X ≤ 5), and single
(0 < X ≤1), where X is the number of cells in which the
clonotype appears.
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Copy number analysis

Copy number variants (CNVs) were assessed using the
CONICSmat package for R [28]. Gene expression values were filtered and normalized as discussed at https://
github.com/diazlab/CONICS. The z-score posterior
probabilities were clustered, with a cut-off score of z=2,
and cell barcodes from the ten clusters (MEN104), seven
clusters (MEN108), and eight clusters (MEN09) were
gathered and visualized on UMAP.
Statistical analysis

Differential gene expression was calculated using the
Wilcoxon rank-sum test (two-sided) as implemented in
the Seurat R package. Bonferroni correction was used to
adjust p-values based upon total number of features in
the dataset. Enriched gene ontology biological pathways
were assessed using ToppGene and the top one or two
biological processes significant after Bonferroni correction were selected.

Results
The dura consists of diverse immune and non‑immune cell
types

To better understand the cellular composition of human
dura, we performed scRNA-seq on samples of human
dura and a subset of matched and non-matched primary meningioma samples derived from patients
undergoing craniotomy for resection of intracranial meningiomas, which arise from the dura and thus are anatomically attached to this meningeal layer (Additional
file 1: Table S1). In surgical resection of meningiomas, if
possible, an adjacent region of dura grossly uninvolved
with the tumor, as defined by the surgeon, is normally
resected to ensure maximal tumor resection and reduce
the risk of recurrence [19, 20]. This grossly uninvolved
dura, which we define as “non-tumor-associated” dura,
was subsequently harvested and used in our analyses.
In total, seven dura samples and six primary meningioma samples (four matched and two non-matched) were
dissociated and analyzed using scRNA-seq (Fig. 1A,
Methods, Additional file 3). We first characterized the
non-tumor-associated dura samples, performing unsupervised clustering and uniform manifold approximation and projection (UMAP) [22] analysis on 22,460 cells
(Fig. 1B). Cells were initially classified into three cell
populations using common markers for endothelial cells
(PECAM1, CDH5, KDR), mesenchymal cells (COL1A1,
COL1A2, LUM, DCN, ACTA2, RGS5), and immune cells
(PTPRC, CD3E, SPI1, CD14) (Fig. 1C and Additional
file 1: Table S2). The majority of cells were immune cells
(10,423 cells), followed by endothelial cells (6283 cells)
and mesenchymal cells (5754 cells). Each patient sample was represented in each of the three major cell types
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(Fig. 1D). These data demonstrate that the dura harbors
a diverse cell population of both immune- and nonimmune-derived cell types.
Immune cell composition of non‑tumor‑associated dura

We next focused on resolving the immune cell (PTPRC+,
which encodes CD45) landscape. To this end, we performed graph-based clustering and UMAP visualization
on 10,423 immune cells (Fig. 2A). Clusters were characterized using a combination of previously reported markers and differentially expressed genes (Fig. 2B, Additional
file 1: Table S2, Additional file 4) [29–38]. This revealed
an appreciable population of lymphoid cells, including
T cells, NK cells, B cells, and plasma-like B cells, as well
as myeloid cells, including monocytes, macrophages,
DCs, and mast cells. Expression of important marker
genes for lymphoid and myeloid cells were visualized
in the UMAP layouts for the indicated cell populations
(Fig. 2C, D, respectively). T cells represented the majority of lymphoid cells observed (5458 cells) and included
naive/central memory T (TCM) cells (1415 cells; which
express SELL, CCR7, LEF1, TCF7, KLF2); CD4+ effector
memory T (TEM) cells (1575 cells; SELL-, CCR7-, IL7R);
CD8+ TEMs (1281 cells; SELL-, CCR7-, IL7R, CD8A,
CD8B, GZMKhi, CXCR3hi); resident memory T (TRM)
cells (251 cells; CD69, NR4A2, IL7R); and CD8+ cytotoxic T cells (CTLs) (936 cells; PRF1, NKG7, ZNF683,
GZMB, CD8A, CD8B). Other lymphoid cell types identified included natural killer (NK) cells (571 cells; PRF1,
NKG7, GZMB, KLRD1, KLRF1, CD3-), B cells (309 cells;
CD79A, MS4A1, MHC class II+); and plasma-like B
cells (35 cells; IGHG3, IGHA1, DERL1, FKBP11). Meanwhile, the monocyte/macrophage/DC population (3889
cells) was identified by monocyte-related (CD14, VCAN,
S100A8, S100A9, MHC class II+), macrophage-related
(CD14, RNASE1, C1QA, C1QC, FCAR, GPNMB), and
DC-related (CD14-, ITGAX, THBD, and IL3RA) markers. As the cell identities of these clusters were not clearly
identifiable by gene marker sets at this resolution, we initially defined this population as a general myeloid compartment composed of monocytes, macrophages, and
DCs. Additionally, we identified mast cells (161 cells;
GATA2, KIT, HPGDS) in the myeloid compartment.
Finally, we sought to compare our data set to a previously published data set [10] that focused on immune
cells in murine dura. We selected the top 20 differentially expressed genes (DEGs) for each general cell type
in the mouse data set, identified their respective human
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homologues, and examined their expression in our
human data set (Additional file 1: Fig. S1A, Additional
file 5). Though not all genes had human homologs nor
were expressed in the human data, we found specific
expression of murine T/NKT, NK, migDC, and D-BAM
markers in the corresponding human immune cell types.
These data demonstrate that human dura is made up of
a diverse population of immune cells, similar to murine
dura, and cell-type-specific gene expression signatures
are similar across species.
To better resolve the monocytes, macrophages, and
DCs, we isolated all myeloid cells (excluding mast cells)
for further analysis, including dimensionality reduction, clustering, and cell type annotation. We performed
graph-based clustering and UMAP visualization on
3889 cells (Additional file 1: Fig. S1B), which revealed
one monocyte/macrophage and two DC populations,
DC-like and migratory DC-like (migDC-like), identified using marker gene sets (Additional file 1: Table S2,
Additional file 1: Fig. S1C). Monocytes and macrophages
were grouped together as these cells expressed varying levels of both marker gene sets. The low expression
levels of markers previously associated with human
microglia, such as AIF1, C1QA, and GPR34 [26], and the
expression of markers commonly associated with monocyte-derived macrophages suggested these cells were
blood-derived rather than tissue resident. Interestingly,
one cluster of cells (C6) was positive for monocyte and
macrophage markers but lacked expression of MHC class
II genes (HLA-DRA, HLA-DRB1), which suggested that
they were myeloid-derived suppressor cells (MDSC-like)
[38]. We similarly analyzed the expression of the top 30
DEGs expressed by matched myeloid cell types reported
by Van Hove et al. [10] (Additional file 1: Fig. S1D, Additional file 5). Overall, we found that the monocyte/macrophage cluster expressed DEGs from each of the murine
myeloid cell types, rather than specific cell types such as
classical monocytes or D-BAMs. Notably, the MDSClike cells under expressed most of these genes. Similarly,
the DC-like cluster highly expressed DEGs from each
of the murine myeloid cell types though C8 particularly
expressed genes differentiating the murine cDC2 cell
type. Finally, we found the migDC-like cluster specifically
expressed genes identifying murine migDCs. Collectively,
these data show the diverse repertoire of myeloid cells
within the dura and some conservation across species.
We further characterized the DC population (DClike: CD14-, ITGAX+ CD1c-, THBDint; migDC-like:

(See figure on next page.)
Fig. 1 Single-cell preparation and sequencing shows diverse cell landscape of human dura. A Illustration of both non-tumor-associated dura and
tumor resection and single-cell library preparation. B UMAP visualization of single-cell RNA-seq data identified by cell type. C Representative gene
expression of select cell type gene markers. D UMAP visualization of single-cell RNA-seq data highlighting cells originating from each individual
patient sample
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CD14- ITGAX- IL3RA+ CCR7+) using unsupervised
clustering and UMAP visualization of 2031 cells (Fig. 2E).
To investigate variation within these cell populations,
we hierarchically clustered the top 10 genes from each
of the top 10 principal components (PCs) and used ToppGene [24] to characterize the functional enrichment
of co-expressed genes (Fig. 2F, Additional file 2). This
highlighted both the cell types present within the tissue,
as well as the biological pathways associated with each
cell type. DC-like clusters were characterized by the following pathways: “cellular response to interleukin-1,”
“positive regulation of cell population proliferation,” and
“response to topologically incorrect protein.” Meanwhile,
migDC-like clusters were characterized by the following
pathway: “cellular response to cytokine stimulus.” Shared
pathways included “response to interferon gamma,” “neutrophil chemotaxis,” and “myeloid cell activation involved
in immune response.” Interestingly, Chen et al. [33] and
Pombo Antunes et al. [36] observed DC clusters similar
to migDC-like cells that likewise differentially expressed
genes such as CCR7 and LAMP3 and suggested that they
are migratory DCs (migDCs) involved in immune cell
recruitment. These data suggested that DCs harbored by
the dura may be playing a role in establishing the dura
immune microenvironment.
Collectively, our analysis demonstrated the presence of
both lymphoid and myeloid cell subsets within the dura
and underscored the dynamic nature of the dura immune
microenvironment.
Endothelial and mesenchymal cells comprise a significant
proportion of cells in non‑tumor‑associated human dura

We next investigated non-immune (PTPRC-) cells by
applying graph-based clustering and UMAP visualization followed by cell type annotation. This revealed three
main cell types identified by previously reported marker
gene sets and differentially expressed genes (Fig. 3A)
[40–43]: endothelial cells (6157 cells; PECAM1, CDH5,
KDR, SELE, VWF), fibroblasts (4132 cells; LUM, DCN,
COL1A1, COL1A2, COL3A1), and mural cells (1368 cells;
ACTA2, MYH11, CNN1, RGS5, PDGFRB, NOTCH3,
MCAM, CSPG4) (Fig. 3B, C, Additional file 4). Though
C18 (132 cells) was initially a small and indeterminate
cluster, as we compared the matched dura and tumor
datasets, further analysis revealed that C18 may represent a potential cluster of tumor cells originating from
MEN08. Specifically, we observed the presence of copy
number variants (CNVs) in 5q and 20q in addition to
DEGs, such as COL9A3 and CRABP1, shared with other
putative tumor clusters described further below (Additional file 4, Fig. 7). Notably, no other samples harbored
detectable populations that could include neoplastic
cells. As non-tumor-associated dura is grossly observed
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to be separate from tumor, the presence of this population could represent an adjacent microscopic cluster of
tumor cells. However, due to the limited number of samples and comparatively small number of observed tumor
cells in general, we were unable to draw any significant
conclusions. We also observed doublets (248 cells),
defined by the co-expression of discordant markers for a
mixture of cell types, although an increase in the number
of transcripts was not detected. The presence of these cell
types is consistent with our understanding of the gross
structure of dura: a moderately vascularized tissue which
harbors a collagen matrix scaffold which underpins the
structure.
To better characterize the fibroblast cell population,
we selected and analyzed these cells using graph-based
clustering and UMAP visualization (Fig. 3D). We hierarchically clustered the top 15 genes of the top 15 PCs to
identify biological programs (Fig. 3E, Additional file 2).
We observed considerable heterogeneity in gene expression profiles and their associated biological pathways
with three major hierarchical clusters arising. Cluster 1, which consisted of C0, C2, C4, C8, and C13, was
enriched in genes related to “regulation of cell population proliferation,” “regulation of DNA binding,” and
“negative regulation of apoptotic process.” These results
suggested a distinct subpopulation of proliferating fibroblasts. Another cluster, characterized by C3, C6, C9, and
C11, was enriched in genes related to “regulation of cell
death” and “cellular response to TGFβ stimulus.” TGFβ
stimulus has been shown to induce fibroblast activation and drive scarring in several organ systems [44, 45]
and suggested perturbation of the fibroblasts. However,
the cause of this activation could be attributed to many
sources, such as biological phenomena occurring within
the tissue or surgical excision. The third cluster, characterized by C1, C5, and C12, was enriched in genes related
to “extracellular matrix organization,” “MHC class II,” and
“proteolysis.” MHC class II upregulation has been shown
to be induced by IFNγ in dermal fibroblasts [46], and
signaling via MHC class II receptors has been shown to
lead to cytokine secretion [47]. Based upon these results,
these cells may have been actively responding to, and
contributing to, immune regulation, in addition to ECM
organization. These results highlighted the heterogeneity
of fibroblasts in the dura and suggested functional specialization of specific subpopulations.
We next compared the fibroblast clusters to murine
meningeal fibroblasts recently described by DeSisto et al.
[39] (Fig. 3F). Specifically, we observed high expression
of markers associated with murine dura fibroblasts, such
as MGP, GJA1, and FXYD5, though not all markers, such
as TGFBI, were highly expressed. We found that markers
used to delineate different dura layers in mouse models,
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Fig. 3 Functionally diverse non-immune cells comprise a significant proportion of human dura. A UMAP visualization of non-immune cells
identified by cell type. B UMAP visualization of select endothelial, mural, and fibroblast markers. C Dot plot of representative gene expression
of select cell type gene markers. D UMAP visualization of fibroblast endothelial cells. E Expression heatmap of top 15 genes of top 15 principal
components of dura fibroblast cells with hierarchical clustering and associated functional enrichment analysis of gene clusters. F Dot plot of select
meningeal fibroblast markers from Desisto et al. [39]. G UMAP visualization of dura endothelial cells. H Expression heatmap of top 15 genes of top
15 principal components of dura endothelial cells with hierarchical clustering and associated functional enrichment analysis of gene clusters. I
UMAP visualization of fenestrated endothelium and blood-brain barrier scores

Wang et al. Genome Medicine

(2022) 14:49

such as MATN4, CTGF, NPPC, and CRABP2, were not
well represented in our data set [48]. Arachnoid markers
TAGLN and OGN, also observed in murine dura fibroblasts, were highly expressed in our data set. Interestingly, although C0 and C13 co-clustered with C2, C4, and
C8 based upon expression of PC genes (Fig. 3E), only C0
and C13 were enriched in both pia (RDH10) and arachnoid markers (GJB6 and CRABP2). Similarly, C11 was
more enriched in arachnoid markers (GJB6 and CRABP2)
than C3, C6, and C9 although they were hierarchically
clustered together. These results suggested heterogeneity within hierarchical clusters and also that further study
may be needed to understand the translation of some
meningeal layer-specific murine markers to patient samples. This conclusion was supported by our investigation
of the enrichment of murine leptomeningeal fibroblastlike cell (FLC) markers reported by DeSisto et al. [39]
based upon data collected by Saunders et al. [49] (Additional file 1: Fig. S2).
We performed a similar analysis on the endothelial
cell population by applying graph-based clustering and
UMAP visualization (Fig. 3G) and hierarchical clustering
of the top 15 genes of the top 15 PCs to identify enrichment of specific biological pathways (Fig. 3H, Additional
file 2). Endothelial cells fell into three major hierarchical populations, with cluster 1 (consisting of C0, C1, C3,
and C6) distinguished by its expression of genes related
to “response to oxidative stress,” “response to abiotic
stimulus,” and “cellular response to TGFβ stimulus.” As
discussed previously, this may reflect endothelial cell biological phenomena or external stimulus, such as surgical
excision or sample processing. Cluster 2, consisting of
C2 and C5, were enriched in genes related to “response
to oxygen levels,” “response to lipid levels,” “response
to interferon gamma,” “collagen-containing ECM,” and
“blood vessel morphogenesis.” These results suggested
that cluster 2 is metabolically active and involved in vasculature development. Finally, cluster 3, which consists of
C4, C7, and C8, exhibits low expression of these genes.
As expected, we found that genes related to blood-brain
barrier function were not enriched although fenestrated
endothelium markers were enriched in hierarchical cluster two (Fig. 3I, Additional file 1: Table S2) [50, 51]. Dural
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fenestrated vessels have been reported and are important for molecule exchange with the blood [14, 52]. These
data demonstrated evidence of a dynamic endothelial cell
landscape in the dura layer composed of subpopulations
with potentially different functions and the presence of
fenestrated endothelium.
Imaging mass cytometry of human dura

Following characterization of human dura at single-cell
resolution, we performed imaging mass cytometry on
available dura samples, DURA02 and DURA05, to visualize the spatial relationship among these cell types. Similar to our approach with scRNA-seq, we sought to first
identify the immune, endothelial, and mesenchymal
cell types using specific cell markers (Additional file 1:
Table S3). We identified vasculature by the presence of
endothelial cells (CD31+, green), which was surrounded
by vascular smooth muscle cells (a-SMA+, red) in sample DURA02 (Fig. 4A). Moreover, we observed diffuse
presence of collagen (magenta) throughout the tissue as
expected. Next, we focused on immune cells, observing concentrated regions of CD45RO expression (cyan)
(Fig. 4B). Focusing on T cells, we observed in region 1
the presence of CD8 T cells based upon overlap of CD8
(cyan) and CD3 (magenta). Furthermore, we observed
the presence of either naïve, or terminally differentiated,
T cells with CD3 and CD45RA overlap. We also observed
in region 1 the presence of cells with overlapping expression of CD14 and CD163, which may represent meningeal macrophages (Fig. 4D) [53–55]. Iba1, a common
microglial marker that is lowly expressed in meningeal
macrophages [53–55], showed some overlap with CD14
and CD163. However, Iba1+CD14-CD163- cells were
likewise observed, suggesting a separate Iba1+ cell population harbored by the dura (Fig. 4D). CD8 T cells were
observed to localize nearby CD163+ cells near the vasculature (Fig. 4D). Notably, the majority of these immune
cells were observed close to, but outside of, defined
CD31+ vasculature. Finally, we observed the presence of
GZMB+ CD11b+ cells, often localized within CD31+
vasculature (Additional file 1: Fig. S3A), indicating circulation of cytotoxic immune cells within non-tumor-associated dura. Imaging of DURA05 demonstrated similar

(See figure on next page.)
Fig. 4 Imaging mass cytometry of a human dura sample reveals intricate spatial relationships among immune, endothelial, and mesenchymal
cell types. A, B Imaging mass cytometry of human dura sample DURA02 labeled with markers specified and specific regions of interest (ROIs)
highlighted by dashed white boxes. C, D Relative position of each image is denoted by marked number in the top left or right corner. Markers are
specified and color coded. White arrows label cells of interest. E, F Imaging mass cytometry of human dura sample DURA05 with markers specified
and the specific region of interest (ROI) highlighted by a dashed white box. G, H Relative position of each image is denoted by marked number
at the top right corner. Markers are specified and color coded. Green arrows represent CD8+ T cells and orange arrows represent CD4+ T cells.
I Hierarchical plot showing the inferred network for MHC-I signaling for immune cells from Fig. 2A. The left and right portions of the plot show
autocrine and paracrine signaling to T cells and remaining immune cells, respectively. Solid circles represent the source of MHC class I ligands and
open circles represent the target of said MHC class I ligands. Circle sizes are proportional to the number of cells and width of connecting lines
indicate the communication probability of said interaction

Wang et al. Genome Medicine

(2022) 14:49

Fig. 4 (See legend on previous page.)

Page 13 of 25

Wang et al. Genome Medicine

(2022) 14:49

results (Fig. 4E–G) with clear CD31+ vasculature surrounded by vascular smooth muscle cells (Fig. 4E) though
immune cells, labeled by CD45RO, were sparser and
localized around the vasculature (Fig. 4F). Both CD8+
T cells (green arrows) and CD4+ T cells (white arrows)
were observed in this sample in region 1 (Fig. 4G). Furthermore, we observed several CD4+ T cells to be adjacent to HLA-DRA+ cells. In contrast, we observed more
overlap among CD14, CD163, and Iba1 (Fig. 4H) with
fewer Iba1+CD14-CD163- cells. Finally, we observed
GZMB+/CD11b+ cells mostly within CD31+ vasculature though infiltration beyond CD31+ vasculature was
also noted (Additional file 1: Fig. S3B).
As cross-presentation of resident macrophages has
been suggested [56], and we observed adjacent CD8+
T cells and CD163+CD14+ macrophages, we investigated whether genes associated with such pathways
may be overrepresented in the single-cell data. Specifically, applying CellChat [57], which infers and analyzes
intercellular signaling pathways, to the immune cell
population from Fig. 2A, we identified several signaling pathways that were significantly represented by
the single-cell data (Additional file 6). In particular, the
monocyte/macrophage/DC population was the most
prominent and significant source of MHC-I-related
ligands targeting the various T cell populations, with the
exception of resident memory T cells (left side of Fig. 4I).
Some autocrine signaling was observed with CD4+ TEM
cells, CD8+ TEM cells, and CD8+ CTLs. Furthermore,
as expected, no significant relationships were observed
with non-T cells as the target (right side of Fig. 4I). While
these data raised the possibility that interaction between
APCs and T cells may occur within the dura tissue itself,
further investigation will be required to fully understand
the functional roles of these immune cells within the
dura as our current conclusions are limited due to the
low number of samples and sites of imaging.
Distinct gene expression profiles demarcate
immune cells infiltrating meningiomas from those
in non‑tumor‑associated dura

In a subset of patients in our cohort, we were able to collect matched meningioma samples together with nontumor-associated dura (Additional file 1: Table S1). We
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analyzed the immune cells of four paired meningioma
and non-tumor-associated dura samples composed of
12,581 cells and used the same markers described above
to identify cell types. Within each cell type, we observed
clear differences in cell state between cells isolated from
each location (Fig. 5A, Additional file 1: Fig. S4A, Additional file 1: Table S2, Additional file 4). Notably, we
observed that T cells, NK cells, monocytes/macrophages/
DCs, and mast cells cluster separately based on tissue
origin, whereas B cells from both dura and tumor clustered together. Though dura T cells consist of naïve/TCM
cells, TEM cells, and CD8+ CTLs, only TRM cells were
observed in the tumor samples.
Comparing top DEGs which differentiate dura-originating from tumor-originating T cells, dura T cells’
DEGs were related to T cell migration and function, such
as CXCR3 [58] and ITGAL [59], as well as cell motility genes SUSD3 and FGD3 [60, 61] (Additional file 7).
In contrast, tumor T cells’ DEGs coded for heat shock
proteins, such as HSPA6, HSPA1A, and HSPA1B in addition to genes related to T cell development and function, such as NR4A1 [62, 63] and NR4A2 [62]. Tumor
NK cells expressed similar DEGs to tumor T cells and
were enriched for genes associated with protein folding and cytokine expression, including genes coding for
heat shock proteins HSPA6, HSPA1B, and HSPA1A, and
IFNG, a common cytotoxic marker (Additional file 7).
However, dura NK cells were enriched for genes that are
associated with NK effector function, such as SH2D1B
[64] and KLRF1 [65]. Interestingly, NLRC3, a negative
regulator of the innate immune response [66], was also
overexpressed. Collectively, these data suggested that
T cells and NK cells might have different functions in
immune regulation depending on tissue of residence.
However, as mentioned previously, although both types
of tissues were processed similarly, the presence of heat
shock proteins may indicate differing responses to the
dissociation process rather than reflecting differing cell
states within respective tissues. Further investigation will
be required to elucidate the clinical implications of these
differences.
To further explore the differences among dura and
tumor monocytes, macrophages, and DCs, we isolated
and reanalyzed both dura and tumor myeloid clusters

(See figure on next page.)
Fig. 5 Non-tumor-associated human dura and meningioma tumor samples show distinctively different immune cell populations. A UMAP
visualization of dura and tumor immune cells identified by cell type. B UMAP visualization of dura and tumor monocyte/macrophage/DCs
identified by cell type. C UMAP visualization of dura and tumor monocyte/macrophages identified by cell type. D UMAP visualization of select
border-associated macrophage (BAM) gene markers and aggregated score. E UMAP visualization of select microglial gene markers and aggregated
score. F Violin plots of M1, M2a, M2b, and M2c macrophage polarization state scores of each cluster from Fig. 5C. G Expression heatmap of the top
15 genes of the top 10 principal components with hierarchical clustering and associated functional enrichment analysis of gene clusters. H UMAP
visualization of dura and tumor DCs identified by cell type. I Expression heatmap of the top 15 genes of the top 10 principal components with
hierarchical clustering and associated functional enrichment analysis of gene clusters
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(excluding mast cells) (Fig. 5B). Marker gene sets were
used to differentiate monocyte/macrophages, DC-like,
and migDC-like cell clusters (Additional file 1: Table S2,
Additional file 1: Fig. S4B). We isolated first dura and
tumor monocyte/macrophage clusters and reanalyzed
them (Fig. 5C). We used markers associated with microglia and border-associated macrophages (BAMs) in
murine models (Additional file 1: Table S2) to determine
the potential origin(s) of these tumor monocyte/macrophages [10, 26] (Figs. 5D, E). Both microglial and BAM
markers were enriched in tumor-only clusters, and not
in dura-only clusters, which suggested that these macrophages were tissue-resident and originated from either
the dura or brain parenchyma rather than blood. Similar
results were observed via immunohistochemical staining of one matched pair of non-tumor-associated dura
and meningioma. Non-tumor-associated dura showed
no presence of somatostatin receptor 2 (SSR2), a sensitive
marker for meningioma tumor cells [67, 68], low levels of
Iba1 (0.228% positive area), CD206 (0.964%), and CD163
(0.368%), and moderate levels of TMEM119 (7.74%), a
selective marker for microglia in the brain parenchyma
[69] (Additional file 1: Fig. S5). Meanwhile, matched
tumor sample showed high levels of SSR2, Iba1 (26.5%),
and TMEM119 (39.5%), and moderate levels of CD206
(8.81%) and CD163 (11.9%). Although these results suggested tumor samples contain higher levels of markers
associated with BAM and microglia, given the limited
number of samples and scope of this study, additional
studies will be needed to determine the origin of these
macrophages. This limitation of our study was further
highlighted by minor discrepancies based on scRNAseq data, IHC staining, and IMC staining as within nontumor-associated dura tissue, a considerable population
of CD163+ cells and Iba1+ cells were observed via
IMC (Figs. 4D, H). Meanwhile, in the IHC staining, we
observed low levels of CD206, CD163, and Iba1 expression in non-tumor-associated dura (Additional file 1:
Fig. S5). Finally, in the scRNA-seq data, we observed in
dura monocyte/macrophages very low levels of MRC1
(which encodes CD206) and heterogenous expression of
CD163 and AIF1 (which encodes Iba1), with high expression of these genes in a small population of cells (Fig. 5D,
E). Potential reasons for these discrepancies include heterogenous populations of immune cells in non-tumorassociated dura that we were unable to capture with the
low number of samples in our data set. Furthermore, as
mentioned previously, dura is currently categorized as
non-tumor-associated from a gross perspective and the
proximity of the non-tumor-associated dura edge to the
dural-based tumor mass may vary from case to case.
Finally, a difference in mRNA and protein levels, lack
of sensitivity to detect rare transcripts, and alterations

Page 16 of 25

in cell state may be contributing factors. As we further
discuss, additional studies will be required to rigorously
define non-tumor-associated dura both from an anatomical and cellular assessment. We then characterized
the potential functionality of these macrophages by first
assessing the macrophage polarization states in both dura
and tumor clusters. Previously reported markers were
aggregated to generate scores for M1, M2a, M2b, and
M2c polarization [25] (Fig. 5F, Additional file 1: Table S4).
Overall, we observed similar M2c scores between dura
and tumor clusters. Interestingly, tumor clusters demonstrated marked elevation of both M1 score, which is associated with a pro-inflammatory immune environment,
and M2a and M2b scores, which are associated with an
anti-inflammatory immune environment [25]. Finally, we
hierarchically clustered the top 15 genes of the top 10 PCs
to infer biological pathways and determine whether they
were distinct based upon tissue source (Fig. 5I, Additional file 2). Overall, we observed a difference in gene
expression between dura monocyte/macrophages and
tumor monocyte/macrophages with respect to biological pathway enrichment. Most prominently, all dura clusters were enriched for genes associated with “response
to sterol” and “myeloid leukocyte migration,” with some
clusters enriched in genes associated with “inflammatory
response” and “negative regulation of DC differentiation.”
Meanwhile, all tumor clusters were enriched for genes
associated with “defense response,” “cellular response to
IFNγ,” and “response to unfolded protein.” In particular,
MHC class II genes such as HLA-DRA and HLA-DRB1
were also upregulated by tumor-specific clusters. Overall,
these results indicated that monocyte/macrophages in
the dura may have different origins and functional profiles compared to those found in the tumor site.
Both dura and tumor DCs were similarly separated and
reanalyzed (Fig. 5H, Additional file 1: Table S2). We analyzed the top 15 genes of the top 10 PCs to infer biological pathways, which revealed considerable heterogeneity
(Fig. 5H, Additional file 2). Notably, all dura DC clusters,
both migDC-like and general DC-like, were enriched in
genes related to “myeloid leukocyte migration.” General
dura DC-like clusters (C0 and C8) were enriched in genes
related to “cellular response to IFNγ” while migDC-like
clusters (C4 and C9) were enriched in genes related to
“cell activation,” such as CCR7 and IL2RA, and “regulation of immune system process.” Tumor-specific DC-like
cluster C7 was enriched in genes related to “negative
regulation of endopeptidase activity” and “inflammatory
response” while C3 was enriched in genes related to “cellular response to cadmium ion” and “defense response.”
Clusters C1, C2, C5, and C6 were enriched in genes
related to “response to other organism” and “regulation
of immune system process.” Dura and tumor DCs also
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have distinct expression profiles, with dura DCs enriched
for genes related to cell migration and cell activation
and tumor DCs enriched for genes that help mount an
immune response.
Given that several studies have demonstrated a functional role for the meninges in CNS immunosurveillance in murine models [14, 70, 71], these comparisons
between tumor- and dura-derived immune cells may
reflect a similar role for the dura in human disease. However, given that meningioma arises from the meninges
itself, another explanation may be that the dura is simply
the tissue site through which immune cells migrate to the
tumor. Further studies, especially of dura collected from
patients with intraparenchymal tumors, will be required
to better understand the role of the meninges in response
to disease in humans.
TCR analysis of human dura and meningioma samples

To understand T cell clonotypic diversity within both
matched dura and meningioma samples, we performed
single-cell sequencing on V(D) J region enriched libraries
from four dura samples and two matched meningioma
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samples (Additional file 1: Table S1). We first analyzed
the relative frequency of T cell receptors (TCRs) by segregating the predominant clonotype (clone 1) from the
rest, which were grouped based upon absolute count (i.e.,
clones 2–5, clones 6–20, clones 21–100, and clones 101–
1000) (Fig. 6A). We observed a greater expansion of the
top 20 clonotypes in the dura samples relative to those in
the meningioma samples.
Following unsupervised clustering and UMAP analysis
of SAMPLE08 and SAMPLE13 T cells alone from Fig. 5A,
we observed a clear segregation of dura T cells from
tumor T cells (Fig. 6B). Moreover, we generated alluvial
plots of the top 15/16 TCRs, ranked by relative frequency
with respect to each sample and represented by a distinct
color, among the two paired dura and meningioma samples to determine the overlap of TCR presence (Fig. 6C,
D, respectively). Strikingly, in the DURA08/MEN08 pair,
all top 15 TCRs were identified at varying levels of expansion in both dura and tumor (Fig. 6C). Furthermore,
DURA08 and MEN08 had a Morisita index, a measurement of the overlap between two data sets, of 0.484
when comparing the entire TCR repertoires of both

Fig. 6 TCR frequency and expression overlap in paired non-tumor-associated dura and meningioma samples. A Clonal frequency of the dominant
TCR, designated by absolute count, and groupings of TCRs ranked by absolute count. B UMAP visualization of dura and tumor T cells identified
by cell type. C, D Alluvial plot demonstrating overlap of the top 15 and 16, respectively, TCRs in paired dura and meningioma samples ranked by
relative frequency
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samples, indicating a considerable amount of TCR overlap between the two samples (Additional file 1: Fig. S6).
In the DURA13/MEN13 pair, 9 of the top 16 most frequently expressed TCRs were present in both DURA13
and MEN13 samples (Fig. 6D). DURA13 and MEN13
have a Morisita index of 0.13, indicating a smaller, but
non-zero, overlap of all TCRs compared to the MEN08
and DURA08 pair (Additional file 1: Fig. S6). These data
illustrated the T cell clonotypic diversity within the
meninges and matched meningioma samples and reveal
that TCR clonotypes can be present within both meningiomas and nearby, non-tumor-associated dura sites.
Single‑cell analysis demonstrates CNV heterogeneity
in meningioma

In addition to analysis of the immune cells from paired
dura and meningioma samples, we also performed copy
number variant analysis on dura and meningioma pairs
to identify putative tumor cells using the R package
CONICSmat [28]. Initially, we identified tumor cells in
only one paired sample (SAMPLE09), suggesting that
tumor cells may have been selected against by the dissociation conditions necessary for dura processing. Therefore, we sequenced two additional meningioma tumor
samples (MEN104 and MEN108) dissociated with the
Miltenyi human tumor dissociation kit (Miltenyi Biotec),
which involves a shorter disaggregation period (Additional file 1: Table S1, Methods). Together, these tumors
represented the three WHO grades (MEN104: grade I,
MEN108: grade II, MEN09: grade III). DURA09, MEN09,
MEN104, consisting of both CD45+ and CD45− fractions, and MEN108, consisting of both CD45+ and
CD45− fractions, samples were analyzed with graphbased clustering and UMAP visualization (Fig. 7A, Additional file 1: Figs. S7A and S7B). Using matched immune
cells as a reference for CNV detection, we identified a
population of cells in each patient sample harboring several chromosomal abnormalities, which we inferred to be
tumor cells (Fig. 7B, Additional file 1: Figs. S7A, S7B, and
S8). Specifically, the most prominent copy number variants observed for MEN104 were deletion of 19q and 22q
(del(19q, 22q)) and amplification of 7p and 7q (amp(7p,
7q)); for MEN108, del(14q, 19q, 22q) and amp(5p, 8q, 9p,
9q, 11p, 15q); and for MEN09 del(1p, 16q) and amp(1q,
6p, 9q, 19q) (Additional file 1: Fig. S8). The majority of
these chromosomal abnormalities are consistent with
previous observations in WHO grades I and II meningiomas [72]. In WHO grade III meningiomas, amp(16q)
and del(6p) are more frequently reported, although
del(16q) and amp(6p) have also been observed. Isolation of the tumor cells reveals three distinct clusters with
unique DEGs (Fig. 7B, C, Additional file 4).
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Following CNV and DEG analysis, we isolated, reanalyzed, and investigated sample-specific meningioma
cells to better characterize the CNV heterogeneity at
the single-cell level. Unsupervised clustering and UMAP
analysis were performed in addition to visualization of
specific groups of cells based on their respective CNV
profiles (Figs. 7D–F). For the tumor cluster derived
from MEN104, three major subclonal populations were
observed: CNV group 1 (CG1) which contained del(19q,
22q) and amp(7p, 7q), CG2 which contained amp(7p,
7q) and may represent the founding clone, and “Other”
which contained the remaining minor CGs consisting of
various combinations of the CNVs (Additional file 1: Fig.
S8A). Differential expression analysis was used to characterize the expression signature of each CNV group
(Additional file 4). To characterize gene expression heterogeneity in the clustered data (Fig. 7D), we analyzed
the expression of the top 10 genes of each of the top 10
PCs (Fig. 7G, Additional file 2). Notably, we observed
that clusters associated with CG1 (C0, C1, C4, C5, C7,
and C8) were enriched in genes associated with several
biological pathways, such as “regulation of cell differentiation,” “response to endogenous stimulus,” “response
to nutrient levels,” and “regulation of cell motility,” while
clusters associated with CG2 (C2, C3, and C6) were
under-enriched. These results suggest CG1 cells may be
more metabolically active and may be undergoing differentiation to develop a metastatic state. We also observed
a cluster of cells (C9) enriched in genes related to “cell
division,” indicating an actively dividing subpopulation.
Similar analyses were performed for MEN108 (Figs. 7E,
H) and MEN09 (Figs. 7F, I). Investigation of MEN108,
unlike with MEN104, revealed several CGs with overlapping clustering patterns as observed with UMAP visualization (Fig. 7E). Analysis of the top PC genes revealed
less heterogeneity as compared to MEN104 (Fig. 7H,
Additional file 2). Most clusters expressed genes related
to “oxidative phosphorylation” and “ECM organization” with cluster-specific expression of “response to
cell population proliferation” and “cellular response to
cytokine stimulus.” One cluster (C10) was enriched in
genes related to “mitotic sister chromatid segregation,”
suggesting an actively proliferating subpopulation of
cells as observed in MEN104. Finally, analysis of MEN09
revealed one CG that characterized the majority of the
cells and two smaller CGs (Fig. 7F). Overall, the majority of clusters showed high expression of genes related
to signaling responses such as “type I interferon signaling pathway” and “cellular response to cytokine stimulus,”
indicating a response of tumor cells to immune surveillance (Fig. 7I, Additional file 2). Several clusters were
enriched for genes related to “angiogenesis,” an important process required for tumor development. Other
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Fig. 7 Analysis of meningioma cells reveals subclonal tumor populations with varying chromosomal abnormalities. A UMAP visualization of one
paired dura and meningioma sample and two additional meningioma samples. B UMAP visualization of predicted tumor cells from MEN104,
MEN105, and MEN09 samples. C Top 10 DEGs expressed in >50% cells of each sample-specific tumor cluster. D-F UMAP visualization of each
individual sample-specific tumor cluster with unsupervised clustering and highlighted by respective CNV group (CG#) identities. G–I Expression
heatmaps of the top 10 genes of the top 10 principal components of sample-specific tumor cells (D-F) with hierarchical clustering and associated
functional enrichment analysis of gene clusters

pathways enriched included “oxidative phosphorylation”
and “response to unfolded protein,” both of which suggested stress responses, and “vesicle organization.” As

with the other tumor samples, an actively dividing cluster
of cells was observed as C8 was enriched in genes related
to “nuclear division.” Overall, analysis of these tumor
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cells, derived from tumors characterized by WHO grades
I, II, and III, at single-cell resolution indicated the presence of CNV heterogeneity. These CGs were sometimes
associated with particular gene expression patterns and
respective functional profiles, as in MEN104. However,
this was not ubiquitous as MEN108 and MEN09 did not
exhibit CNV-associated gene expression profiles.

Discussion
In this study, we presented the first comprehensive
scRNA-seq analysis of human non-tumor-associated
dura and primary meningioma tumor samples. The
meninges have assumed growing importance in the study
of CNS immunity and pathobiology as it has become
clearer that they represent a dynamic microenvironment
composed of unique cells with distinct immunologic, as
well as non-immunologic, functions rather than a purely
structural tissue barrier. To better understand this tissue
site, we characterized both the immune and non-immune
cell landscapes in non-tumor-associated dura in addition
to analyzing both the gene and protein expression profiles of identified cell types using multiple platforms.
Building upon previous studies that characterized the
immune microenvironment in murine dura [10, 14, 73],
we observed a diverse collection of immune cells associated with both human non-tumor-associated dura and
meningioma. The dura harbored several distinct T cell
types ranging from T cells with a naive gene expression
profile to those with cytotoxic profiles. The presence of
these T cell subtypes may reflect ongoing immune surveillance by lymphocytes in non-tumor-associated dura,
which has been demonstrated in murine models [14,
73]. Meanwhile, the majority of T cells in meningioma
samples were TRM cells, which play a pivotal role in
protective immunity and have been identified in many
human solid cancers and brain infection [74]. Notably,
the majority of TRM cells we observed were CD8− while
current literature has focused on the role of CD8+ TRM
cells in the immune response, especially against solid
cancers. Furthermore, we observed an enrichment of
BAM and microglial gene signatures, both of which are
tissue-resident phenotypes, in tumor samples compared
to non-tumor-associated dura samples and supported
these findings with IHC staining. Although minor discrepancies in BAM signature expression were observed
among the scRNA-seq, IHC, and IMC data, potential
reasons include the heterogeneity of dura samples that
was not captured by our limited number of samples, in
addition to lack of correlation between mRNA and protein expression, transcripts that are not detected by
scRNA-seq (“dropouts”), and potential cell state changes
due to sample processing. BAMs have been described to
play immune roles, such as support and maintenance of
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barrier function and surveillance of antigens, within the
meninges [75] and microglia have been implicated in
brain parenchyma homeostasis [76]. For these reasons,
further investigation will be required to understand the
function of these cells in non-tumor-associated dura
compared to those present in the meningioma samples
themselves. The significant difference in gene expression
and associated functional profiles of immune cells based
upon tissue origin warrants further investigation, as these
differences may indicate targetable pathways to decrease
tumor growth and the likelihood of recurrence.
Previous investigation in murine dura has established the role of the sinus vasculature in murine dura
in allowing homeostatic T cell surveillance, in addition to demonstrating interaction between T cells and
APCs adjacent to the sinus [70]. Our imaging suggested
similar interactions may be occurring in human nontumor-associated dura as we observed co-localization
of CD4+ T cells and HLA-DRA+ cells in addition to
CD8+ T cells and CD163+ macrophages near CD31+
stained vasculature. In addition, we found within the
single-cell data that the monocyte/macrophage/DC
population was a prominent source of MHC-I-related
ligands while the T cells were prominent sources of
respective targets. However, rigorous future studies
will be required to determine whether such interactions
occur within human dura.
By analyzing TCR clonotype diversity, we observed that
the majority of T cells with highly expanded clonotypes
expressed a cytotoxic phenotype in non-tumor-associated dura samples. Notably, tumor infiltrating T cells
were less expanded and did not exhibit a robust cytotoxic
phenotype, again illustrating a distinction between these
environments though we were limited by the number
of samples. In contrast, there were shared T cell clonotypes between paired non-tumor-associated dura and
meningioma samples. Because meningiomas arise from
the dura, we suggested that tumor-specific T cells could
enter meningiomas through the same blood vessels supplying the surrounding non-tumor-associated dura tissue
[52, 77] following a priming event either within the dura
or elsewhere. As a result of the presence of immune cell
infiltrate in non-tumor-associated dura tissue observed
via IMC and shared clonotypes in paired dura and meningioma samples, we suggested that our non-tumorassociated dura may not be representative of normal dura
in a healthy patient. In fact, our data indicated that an
immune response may be occurring within the dura tissue itself. However, further investigation will be required
to understand the mechanism behind T cell response
to meningiomas, though the existence of shared T cell
clones underscore the involvement of the dura in this
process.

Wang et al. Genome Medicine

(2022) 14:49

Meanwhile, investigating non-immune cells in human
non-tumor-associated dura, we observed the presence
of endothelial cells, fibroblasts, and mural cells, each of
which plays an important role in the maintenance of the
dura layer. The dura mater contains an abundant anastomotic arterial network [78], and in our samples, we
observed an abundant presence of endothelial cells that
were enriched in genes related to “blood vessel development” and “regulation of cell population proliferation.”
Furthermore, as previously described, we observed the
presence of fenestrated endothelium markers and a lack
of blood-brain barrier related markers [14]. The presence
of mural cells, which have been shown to be present and
regulate vascular diameter and blood flow in the CNS
[50], was also observed in our samples. However, while
the distinction between pericyte and vascular smooth
muscle cell can be made based upon immunostaining techniques [79], this distinction is difficult to make
based upon specific gene markers. As a result, further
studies will be required to determine specific vasculature location and correlated gene expression profiles.
Finally, fibroblasts have been shown to play an important
role in CNS development [1] and may even contribute
to nociceptive signaling in murine models [80]. In our
human dura samples, we observed an abundant presence
of fibroblasts that contained a diverse gene expression
profile enriched in biological pathways mainly concerning ECM development and response to various stimuli.
These results indicated a dynamic cellular population
in the human meninges, even beyond the development
phase, that requires further investigation to better characterize and understand its role in maintaining dura
mater homeostasis beyond a purely structural function.
We also showed expression of dura-specific fibroblast
markers generated from murine models [39], suggesting
cross-species conservation.
Finally, from our analysis of patient-specific meningioma tumor cell populations, in which all three WHO
grades were represented, we observed varying levels of
CNV heterogeneity and heterogeneity of gene expression profiles across all samples. For one sample, we found
CNV heterogeneity to be associated with specific gene
expression signatures and associated biological pathways, while for the other two, such associations were
not observed. Given our low number of samples taken at
one time point, further studies are needed to understand
the development of meningiomas and the relationship
among these subclonal tumor populations. Specifically,
with more samples, we can better determine the relationship among CNV heterogeneity, gene expression,
and functional properties of meningioma cells. Interestingly, such transcriptomic intratumoral heterogeneity, in
addition to epigenetic heterogeneity, has been associated
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with high-grade meningiomas at a bulk-tissue level with
accompanying single-cell investigation of human cerebral
organoids [81]. However, beyond this, investigation into
primary meningioma tumor samples at a single-cell resolution has been relatively unexplored.
Our study provides the first scRNA-seq characterization of both immune and non-immune cell types in
human non-tumor-associated dura and primary meningioma tumor samples. Similar to collaborative efforts
such as the Human Cell Atlas [82], these data are a
resource for furthering our understanding of the cellular
composition of human dura. However, we recognize that
there are several limitations of our study. From a sample collection standpoint, non-tumor-associated dura
is determined based upon gross assessment of the relative location of tumor and dura by the surgeon. This may
lead to heterogeneity in dura samples and potential presence of microscopic tumor clusters, as observed in one of
our samples. As a result, we recognize that our conclusions are limited to describing the composition and cell
states within non-tumor-associated dura collected from
patients with meningioma, which may or may not be
similar to normal, homeostatic dura tissue or dura tissue
from patients with non-tumor conditions. However, this
caveat does not limit the implications of our work as we
make important observations regarding both the immune
and non-immune cell compositions of human dura and
the potential roles they have in response to disease,
building upon the work performed in murine models
[10, 14, 36, 70]. We acknowledge that there are additional
limitations including the number of samples in our study,
potential bias due to sample preparation, and limited validation of cell type presence via IHC and IMC. Further
studies will be required to develop our understanding of
the role of dura in the context of meningioma in addition
to comparing how this role may change in other tumor
settings depending on the type of tumor present, such as
intraparenchymal brain tumors like glioblastoma multiforme or brain metastases. Additional studies will also be
required to investigate whether our current standard for
resecting meningioma tumors, and their respective dura
borders, can be improved by systematically investigating
the cellular composition, and the respective cell states, of
the dura based upon distance from the primary tumor.
We also aim to investigate additional opportunities to
explore this tissue site across the full extent of its anatomic locations in normal and non-tumor settings. Given
the growing evidence implicating the importance of the
dura in biological pathways, such as immunosurveillance
of the CNS, and in particular brain tumors [17, 83], and
its current relevance in practical medical settings, such as
embolization of the middle meningeal artery for new or
recurrent chronic subdural hematoma [18], we envision
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there to be significant translational and clinical implications of an improved understanding of the biology of the
human dura in the context of disease.

Conclusions
Our characterization of human non-tumor-associated
dura and primary meningioma tumor samples suggests new roles of the human dura in the context of CNS
immune surveillance and reveals CNV heterogeneity in
meningioma. The identification of a diverse repertoire of
immune cells and associated phenotypes in dura, imaging
studies that suggest co-localization of T cells and APCs
within the dura tissue, and overlapping TCRs between
dura and meningioma samples suggest the presence of
immunosurveillance in the dura. Meanwhile, investigation of non-immune-related cells suggests that the dura
is a dynamic, and constantly developing, layer of tissue
and demonstrates subclonal heterogeneity in primary
meningioma. The implications of this study are important as first, they contribute to the growing consensus
that the dura layer plays a pivotal role in CNS immunosurveillance. Just as importantly, our study provides evidence of such biological phenomena in human samples,
providing a foundation for both pre-clinical models and
future translational studies.
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